[{"id":"5f8ce650-2a00-4f62-8957-6ea4665a0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02473731","created_at":"2021-01-18T11:54:36.133Z","updated_at":"2024-07-02T16:36:57.461Z","phase":"Phase 1","brief_title":"A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients","source_id_and_acronym":"NCT02473731","lead_sponsor":"Celldex Therapeutics","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-3379"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 09/22/2016","primary_completion_date":" 09/22/2016","study_txt":" Completion: 10/10/2016","study_completion_date":" 10/10/2016","last_update_posted":"2019-08-01"},{"id":"2c3f46c2-6b83-4807-b2db-f86cdef891e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02014909","created_at":"2021-01-18T09:12:56.219Z","updated_at":"2024-07-02T16:37:19.624Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors","source_id_and_acronym":"NCT02014909","lead_sponsor":"Celldex Therapeutics","biomarkers":" EGFR • HER-2 • KRAS • BRAF","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-3379"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 05/25/2017","primary_completion_date":" 05/25/2017","study_txt":" Completion: 06/05/2017","study_completion_date":" 06/05/2017","last_update_posted":"2017-07-24"}]